Percutaneous Closure of Postinfarction Ventricular Septal Defect, an early alternative to surgery.

Original title: Percutaneous Closure of Postinfarction Ventricular Septal Defect: In-Hospital Outcomes and Long-Term Follow-Up of UK Experience. Reference: Circulation. 2014 Jun 10;129(23):2395-402. As a mechanical post AMI complication, interventricular communication carries a grim prognosis. Surgery has achieved reasonable outcomes but only for those patients who survive the acute phase of healing. Percutaneous closure is a viable early alternative. <a href="https://solaci.org/en/2014/07/01/percutaneous-closure-of-postinfarction-ventricular-septal-defect-an-early-alternative-to-surgery/" title="Read more" >...</a>

Cohort with left main coronary injury of SYNTAX. Final monitoring at 5 years.

Original title: Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Reference: Morice MC et al. Circulation. 2014 Jun 10;129(23):2388-94.   Current guidelines recommend CABG as the strategy of choice for treating lesions of<a href="https://solaci.org/en/2014/06/19/cohort-with-left-main-coronary-injury-of-syntax-final-monitoring-at-5-years/" title="Read more" >...</a>

1-Year Clinical Outcomes of Everolimus-Eluting Bioresorbable Vascular Scaffolds in Diabetic Patients

Original title: 1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds A Pooled Analysis of the ABSORB and the SPIRIT Trials. Reference: Muramatsu T et al. JACC CardiovascInterv. 2014 May;7(5):482-93. This study included ABSORB, ABSORB Extend and SPIRIT patients. A total of 136 diabetic patients and 415 non diabetic receiving everolimus-eluting bioresorbable scaffolds (Absorb) and<a href="https://solaci.org/en/2014/06/10/1-year-clinical-outcomes-of-everolimus-eluting-bioresorbable-vascular-scaffolds-in-diabetic-patients/" title="Read more" >...</a>

Orbital Atherectomy improves calcified lesions treatment outcomes

Original title: Pivotal Trial to Evaluate the Safety and Efficacy of the Orbital Atherectomy System in Treating de Novo, Severely Calcified Coronary Lesions (ORBIT II) Reference: Jeffrey Chambers, et al. JACC Intervention 2014;7:510-8 Severely calcified coronary lesions, traditionally associated to difficult or impossible stent implantation, asymmetric stent expansion, higher post procedural events rate, more restenosis, more lesion revascularization,<a href="https://solaci.org/en/2014/06/02/orbital-atherectomy-improves-calcified-lesions-treatment-outcomes/" title="Read more" >...</a>

Higher percentage of strut coverage in biodegradable polymer DES vs. durable polymer DES. Strut level OCT analyses

Original title: Randomized comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. Reference:  EuroIntervention 2014; 9-online publish-ahead-of-print February 2014   The aim of this study was to compare strut coverage at six months follow up after Nobori biolimus eluting stent (N- BES) implantation versus Cypher Select sirolimus eluting stent (SES) implantation.<a href="https://solaci.org/en/2014/05/27/higher-percentage-of-strut-coverage-in-biodegradable-polymer-des-vs-durable-polymer-des-strut-level-oct-analyses/" title="Read more" >...</a>

Dedicated two everolimus eluting stent strategies improve bifurcation PCI outcomes

Original title: Dedicated two-stents technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: The EES-bifurction study. Reference: Nisharamed I. Kherada, et al. International Journal of Cardiology 2014;174:13-17   Bifurcation PCI, especially 1.1.1 Medina bifurcation lesions PCI, is particularly challenging and has been associated with increased restenosis. The use of drug eluting stents (DES) associated to<a href="https://solaci.org/en/2014/05/27/dedicated-two-everolimus-eluting-stent-strategies-improve-bifurcation-pci-outcomes/" title="Read more" >...</a>

Severe coronary calcification is a predictor of coronary events in acute coronary syndromes

Original title: Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Pooled Analysis From the HORIZONS and ACUITY Trials. Reference: Philippe Généreux, et al. J Am Coll Cardiol 2014;63:1845-54 Calcification of the arteries has always been a challenge and a generator of problems during coronary angioplasty, but its impact on acute coronary syndromes has not<a href="https://solaci.org/en/2014/05/21/severe-coronary-calcification-is-a-predictor-of-coronary-events-in-acute-coronary-syndromes/" title="Read more" >...</a>

Angioplasty versus surgery in patients with critical lower limb ischemia

Original title: Comparative effectiveness of endovascular andsurgical revascularization for patients with peripheralartery disease and critical limb ischemia: Systematicreview of revascularization in critical limb ischemia. Reference: W Schuyler Jones, et al. (Am Heart J 2014; 167:167:489-498.e7) Lower limbs critical ischemia is the most severe condition of PAD. The morbidity, mortality and costs related thereto are well documented; however, the<a href="https://solaci.org/en/2014/05/14/angioplasty-versus-surgery-in-patients-with-critical-lower-limb-ischemia/" title="Read more" >...</a>

Blush reduction in a not responsible vessel is a prognostic marker in those receiving angioplasty in the culprit vessel.

Original title: Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneos Coronary OIntervention for Acute Coronary Síndromes. Analysis From ACUITY Trial. Reference: Alexandra Lansky, et al. JAAC Cardiovascular Intervention 2014,7:266-275 In Non ST elevation Acute Coronary Syndrome (NSTE-ACS) is demonstrated that revascularization of the culprit vessel is beneficial, but strategy it is not yet clear<a href="https://solaci.org/en/2014/05/09/blush-reduction-in-a-not-responsible-vessel-is-a-prognostic-marker-in-those-receiving-angioplasty-in-the-culprit-vessel/" title="Read more" >...</a>

Angioplasty in sirolimus – eluting stent restenosis is safe and effective beyond the change of drug.

Original title: Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the ISAR-DESIRE 2 trial. Reference: Sebastian Kufner, et al. Cardiovascular Revascularization Medicine 2014, 15:69-75.   DES restenosis has always generated a challenge and a puzzle when defining the strategy of revascularization by angioplasty: A quite used concept was to switch to<a href="https://solaci.org/en/2014/05/06/angioplasty-in-sirolimus-eluting-stent-restenosis-is-safe-and-effective-beyond-the-change-of-drug/" title="Read more" >...</a>